IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
IceCure Medical completed the first patient treatment in its ChoICE post-marketing study evaluating ProSense cryoablation for low-risk breast cancer. The first patient was treated at West Cancer Center & Research Institute in Germantown, Tennessee by Dr. Richard E. Fine; the study plans to enroll roughly 400 patients across up to 30 U.S.
Key figures
- Drug Name
- ProSense cryoablation system
- Phase Of Trial
- Post-marketing study (FDA-cleared indication)
- Planned sites
- up to 30 U.S. clinical sites
- Planned enrollment
- approximately 400 patients
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.